Therefore, APOE–POLG interaction not only influences the age of diagnosis of PD but also impacts cerebrospinal fluid (CSF) biomarkers, offering potential avenues for early diagnosis and targeted therapies. This evidence concerns the gene POLG and Parkinson disease.